Cross-sectional study describes methods and timing of reporting safety and efficacy trials for FDA-approved drugs, implying potential gaps in communication.
This cross-sectional study describes methods and timing of dissemination of the results of efficacy and safety trials outlined in postmarketing requirements for novel drugs approved by the US Food and Drug Administration (FDA).
No takes yet. Share an insight, caveat, or question.
Siebert et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: